Lipocine Inc. Cash Flow Statement
LPCN|9 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Lipocine Inc. used $1M in operating cash flow and negative free cash flow of $1M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $8.4K | -$16.4M | -$10.8M | -$634.4K | -$21.0M | -$13.0M | -$11.7M | -$19.0M | $3.9M |
| Depreciation & Amortization | $41.1K | $28.7K | $9.5K | $380 | $3.6K | $15.4K | $18.6K | $32.0K | $42.6K |
| Operating Cash Flow | -$1.2M | -$11.9M | -$12.0M | -$4.4M | -$15.3M | -$11.7M | -$12.1M | -$18.3M | -$3.2M |
| Capital Expenditures | $90.1K | $13.2K | $133.8K | $7.6K | $7.6K | - | - | $59.6K | $12.3K |
| Free Cash Flow | -$1.3M | -$11.9M | -$12.1M | -$4.4M | -$15.3M | - | - | -$18.3M | -$3.2M |
| FCF Margin | -11.7% | 416.7% | -2420.5% | -27.4% | -94.9% | - | - | - | -41.4% |